Synthetic Biologics

Synthetic Biologics - Overview

Synthetic Biologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics to protect and restore the gut microbiome and produce small molecules to address specific diseases and conditions. The company's lead candidates are designed to target specific pathogens that cause serious infections and gastrointestinal disorders. Synthetic Biologics' lead program, SYN-010, is a recombinant oral lysozyme designed to protect the gut and destroy bacterial pathogens, with potential applications in various gastrointestinal indications. The company also has a pipeline of other synthetic biologic and small molecule candidates in development for the prevention and treatment of Clostridioides difficile infection, inflammatory bowel diseases, and phenylketonuria. Synthetic Biologics is committed to harnessing the power of synthetic biology to develop innovative therapies that address critical patient needs.'

Competitive Insights

1. Focus on developing therapeutic candidates leveraging its proprietary Microsynthia® technology for the prevention and treatment of serious infections in the gut microbiome, including Clostridioides difficile infection and phenylketonuria.

2. Collaborative partnerships with leading academic institutions and industry players, such as the University of California, San Diego and Merck KGaA, to expand its pipeline and enhance research capabilities.

3. Strong intellectual property portfolio, including over 35 issued and pending patents, providing a competitive edge in the development of novel microbiome-targeted therapeutics.

4. Experienced management team with a track record of success in bringing innovative biotech products to market, including the former CEO of Alkermes plc and the former CMO of Cubist Pharmaceuticals.

5. Strategic focus on addressing unmet medical needs in the gastrointestinal tract, a large and growing market with significant potential for therapeutic interventions.

Business insights

1. Synthetic Biologics focuses on developing therapeutic products that utilize the body's natural response to heal and protect against infection. Their lead candidate, SYN-010, is a proprietary, investigational, orally administered, monoclonal antibody-based therapeutic designed to prevent recurrent Clostridioides difficile infection.

2. The company's pipeline also includes SYN-020, an oral estriol drug candidate for the prevention of relapses in patients with ulcerative colitis, and SYN-030, an intranasal formulation of live Lysozyme for the prevention of respiratory infections.

3. Synthetic Biologics employs a unique, proprietary, and modular approach to microbiome-directed therapeutics, which involves designing and engineering specific microbes to perform targeted functions.

4. The company has a strategic collaboration with Intrexon Corporation (XON) for the development and commercialization of certain microbiome-directed therapeutics.

5. Synthetic Biologics is headquartered in Rockville, Maryland, and has additional facilities in Lexington, Massachusetts, and Raleigh, North Carolina.

Synthetic Biologics Market Portfolio | Comprehensive Overview

Browse Our Research Portfolio In Synthetic Biologics Markets

Synthetic Biologics features in

Industries

Health Care

Segments

Pharmaceuticals

Markets

Pharmaceuticals